Skip to main content
. Author manuscript; available in PMC: 2019 Oct 31.
Published in final edited form as: J Am Coll Cardiol. 2019 Oct 15;74(15):1910–1923. doi: 10.1016/j.jacc.2019.07.081

Central Illustration. Dabigatran treatment ameliorates AD pathogenesis in the TgCRND8 mouse model.

Central Illustration.

Long-term treatment with dabigatran prevents fibrin deposition in the AD brain, ameliorating amyloid pathology and neuroinflammation and preserving BBB integrity and CBF. Aβ=amyloid-β; AD=Alzheimer’s disease; BBB=Blood-Brain Barrier.